Liver Research, published by KEAI PUBLISHING LTD, is a pioneering open-access journal dedicated to advancing knowledge in the fields of hepatology and gastroenterology since its inception in 2017. With a significant impact factor reflected in its 2023 category quartiles (Q2 in Gastroenterology and Q3 in Hepatology) and Scopus rankings, it stands as an essential platform for researchers, clinicians, and students seeking to stay updated on the latest developments and breakthroughs in liver diseases and treatments. Based in Beijing, China, this journal nurtures collaboration and innovation, ensuring that valuable insights are freely accessible to a global audience. As it continues its coverage until 2024, Liver Research plays a pivotal role in bridging the gap between research and clinical practice, making it a cornerstone resource for those committed to improving liver health.

SEMINARS IN LIVER DISEASE is a premier journal dedicated to advancing the field of hepatology, published by THIEME MEDICAL PUBL INC. Established in 1981, it has become a respected resource within the academic community, providing high-quality peer-reviewed articles that cover a broad range of topics related to liver diseases. With an impressive impact factor and recognized as a Q1 journal in the hepatology category, it ranks 17th out of 82 journals in the field, placing it in the top 21% of its category according to Scopus rankings. Although it does not offer open access, the journal’s rigorous standards and extensive network ensure that it reaches a wide audience of clinicians, researchers, and students, fostering knowledge and innovation in liver disease management. The journal's objectives focus on disseminating critical insights and promoting informed discussions that can pave the way for future research and clinical advancements in hepatology.

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

HPB is a premier journal dedicated to advancing the fields of Gastroenterology and Hepatology, published by Elsevier Science Ltd. With an impressive impact factor reflective of its high-quality research output, HPB has earned its place as a Q1 journal in Gastroenterology and Q2 in Hepatology as of 2023. The journal, available in both print and electronic formats (ISSN: 1365-182X; E-ISSN: 1477-2574), serves as a vital platform for multidisciplinary research, encompassing clinical and experimental studies, aimed at improving patient care and outcomes related to liver and biliary diseases. Since its inception in 2000, HPB has published influential articles that have shaped practice and policy in the field. Located in the United Kingdom, at 125 London Wall, London EC2Y 5AS, the journal is poised to continue its mission of fostering innovation and collaboration among researchers, healthcare professionals, and academicians worldwide.

The Journal of Gastrointestinal and Liver Diseases, published by MEDICAL UNIV PRESS in Romania, serves as a pivotal platform for the dissemination of significant research in the fields of gastroenterology and hepatology. Established in 2006, this journal has evolved over the years, currently holding a Q3 rank in Gastroenterology and a Q2 rank in Medicine (miscellaneous), reflecting its commitment to high-quality scholarship and impactful contributions to medical science.

With an ISSN of 1841-8724 and an E-ISSN of 1842-1121, the journal engages a diverse readership of researchers, clinicians, and students passionate about advancing knowledge in gastrointestinal and liver health. While it currently does not operate under an open access model, the journal remains a vital resource for those seeking to stay updated on the latest developments and emerging trends in the field. As it converges towards a broader impact, projected through its coverage until 2024, the Journal of Gastrointestinal and Liver Diseases continues to contribute to the academic landscape, encouraging innovation and comprehensive understanding in digestive health.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.